Sanofi will make tough investment decisions, double down on a more focused pipeline, cut spending and restructure its business units, including separating out consumer health care. Those were key takeaways from the company's capital markets day on 10 December in Cambridge, MA, where CEO Paul Hudson outlined his turnaround plan for the company.
Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.